Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy

  • Kadowaki, Shigenori (Department of Clinical Oncology, Aichi Cancer Center Hospital) ;
  • Komori, Azusa (Department of Clinical Oncology, Aichi Cancer Center Hospital) ;
  • Takahari, Daisuke (Department of Clinical Oncology, Aichi Cancer Center Hospital) ;
  • Ura, Takashi (Department of Clinical Oncology, Aichi Cancer Center Hospital) ;
  • Ito, Seiji (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Tajika, Masahiro (Department of Endoscopy, Aichi Cancer Center Hospital) ;
  • Niwa, Yasumasa (Department of Endoscopy, Aichi Cancer Center Hospital) ;
  • Oze, Isao (Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute) ;
  • Muro, Kei (Department of Clinical Oncology, Aichi Cancer Center Hospital)
  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Systemic chemotherapy for patients with metastatic gastric cancer (MGC) is generally palliative, although some patients experience long-term survival after treatment. Thus, we identified clinical characteristics that are associated with long-term survival of patients with MGC after palliative chemotherapy. Materials and Methods: We retrospectively reviewed 514 MGC patients who received systemic chemotherapy at our institution from 2001 to 2008. To identify clinical predictors of survival beyond 2 years, multivariate logistic regression analyses were performed, and 5-year survival rates were estimated among MGC patients following chemotherapy. Results: Among 514 patients, 96 (19%) and 16 (3%) survived beyond 2 and 5 years, respectively, and performance status of 0 or 1 (odds ratio [OR]=3.39; p=0.01), previous gastrectomy (OR=1.86; p=0.01), single metastatic site (OR=1.80; p=0.03), and normal alkaline phosphatase levels (OR=2.81; p<0.01) were identified as independent predictors of long-term survival. Of the 16 5-year survivors, six were alive at the end of the study and showed no evidence of disease despite cessation of chemotherapy. Conclusions: The present data demonstrate distinct clinical characteristics that are associated with long-term survival of MGC patients, and indicated that palliative chemotherapy can be curative in highly selected patients.

Keywords

References

  1. N, Yamamoto S, Fukuda H, et al (2009). Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol, 10, 1063-9. https://doi.org/10.1016/S1470-2045(09)70259-1
  2. Cancer Information Service, National Cancer Center, Japan (2013). Cancer motality (1958-2013).xls. [Internet]. Available from: http://ganjoho.jp/professional/statistics.
  3. Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. https://doi.org/10.1056/NEJMoa073149
  4. Ford HE, Marshall A, Bridgewater JA, et al (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol, 15, 78-86. https://doi.org/10.1016/S1470-2045(13)70549-7
  5. Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. https://doi.org/10.1023/A:1008243606668
  6. Hosokawa A, Sugiyama T, Ohtsu A, et al (2007). Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol, 42, 533-8. https://doi.org/10.1007/s00535-007-2059-3
  7. Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. Asian Pac J Cancer Prev, 13, 3869-72. https://doi.org/10.7314/APJCP.2012.13.8.3869
  8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  9. Kadowaki S, Komori A, Narita Y, et al (2014). Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment. Int J Clin Oncol, 19, 656-61. https://doi.org/10.1007/s10147-013-0610-1
  10. Kang JH, Lee SI, Lim do H, et al (2012). Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol, 30, 1513-8. https://doi.org/10.1200/JCO.2011.39.4585
  11. Koizumi W, Narahara H, Hara T, et al (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol, 9, 215-21. https://doi.org/10.1016/S1470-2045(08)70035-4
  12. Koo DH, Ryoo BY, Kim HJ, et al (2011). A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol, 68, 913-21. https://doi.org/10.1007/s00280-011-1561-8
  13. Lee J, Lim T, Uhm JE, et al (2007a). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol, 18, 886-91. https://doi.org/10.1093/annonc/mdl501
  14. Lee SS, Lee JL, Ryu MH, et al (2007c). Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol, 37, 30-7.
  15. Park IH, Kim SY, Kim YW, et al (2011). Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol, 67, 127-36. https://doi.org/10.1007/s00280-010-1296-y
  16. Pyrhonen S, Kuitunen T, Nyandoto P, et al (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. https://doi.org/10.1038/bjc.1995.114
  17. Saitoh H, Boku N, Ohtsu A, et al (2000). Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy. Gastric Cancer, 3, 106-9. https://doi.org/10.1007/PL00011694
  18. Schildberg CW, Weidinger T, Hohenberger W, et al (2014). Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis. World J Surg, 38, 419-25. https://doi.org/10.1007/s00268-013-2293-1
  19. Takahari D, Boku N, Mizusawa J, et al (2014). Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist, 19, 358-66. https://doi.org/10.1634/theoncologist.2013-0306
  20. Tetzlaff ED, Faust J, Ajani JA (2006). Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer, 9, 140-3. https://doi.org/10.1007/s10120-006-0363-x
  21. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  22. Thuss-Patience PC, Kretzschmar A, Bichev D, et al (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer, 47, 2306-14. https://doi.org/10.1016/j.ejca.2011.06.002
  23. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  24. Yamamoto M, Matsuyama A, Yoshinaga K, et al (2012). Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. Oncol Lett, 3, 662-6.
  25. Yoshida M, Ohtsu A, Boku N, et al (2004). Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol, 34, 654-9. https://doi.org/10.1093/jjco/hyh120

Cited by

  1. Factors Affecting Long Term Survival for Metastatic Gastric Cancer Treated with Chemotherapy vol.16, pp.2, 2016, https://doi.org/10.7704/kjhugr.2016.16.2.97
  2. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety vol.16, pp.3, 2017, https://doi.org/10.1080/14740338.2017.1273348